

## Clinical Policy: Continuous Insulin Delivery Systems (V-Go, Omnipod)

Reference Number: CP.PHAR. 505

Effective Date: 12.01.20

Last Review Date: 11.20

Line of Business: Commercial, Medicaid, HIM-Medical Benefit

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### Description

The following are continuous insulin delivery systems requiring prior authorization:

- V-Go<sup>®</sup> Wearable Insulin Delivery Device
- Omnipod<sup>®</sup> Insulin Management System
- Omnipod DASH<sup>™</sup> Insulin Management System

### FDA Approved Indication(s)

#### V-Go Wearable Insulin Delivery Device

- **Use:** subcutaneous delivery of insulin to provide basal-prandial control.
  - The V-Go 20 Disposable Insulin Delivery Device is indicated for continuous subcutaneous infusion of 20 Units of insulin in one 24- hour time period (0.83 U/hr) and on-demand bolus dosing in 2-Unit increments (up to 36 Units per one 24-hour time period) in adult patients requiring insulin.
  - The V-Go 30 Disposable Insulin Delivery Device is indicated for continuous subcutaneous infusion of 30 Units of insulin in one 24- hour time period (1 .25 U/hr) and on-demand bolus dosing in 2-Unit increments (up to 36 Units per one 24-hour time period) in adult patients requiring insulin.
  - The V-Go 40 Disposable Insulin Delivery Device is indicated for continuous subcutaneous infusion of 40 Units of insulin in one 24- hour time period (1 .67 U/hr) and on-demand bolus dosing in 2-Unit increments (up to 36 Units per one 24-hour time period) in adult patients requiring insulin.
- **Populations:** Adult patients requiring insulin.\*  
*\*Patients who have to make regular adjustments or modifications to their basal rate during a 24-hour period, or whose amount of insulin used at meals requires adjustments of less than 2-Unit increments, should not use V-Go as it may result in hypoglycemia. V-Go has not been studied in patients who are pregnant or in patients diagnosed with gestational diabetes.*
- **Components:** 1) V-Go device, 2) EZ Fill device
- **User guide and related resources:** <https://www.go-vgo.com/hcp/wp-content/uploads/sites/2/2019/12/ART-1361-Rev-A-V-Go-IFU-2019-V4.pdf>.

#### Omnipod Insulin Management System

- **Use:** subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin.
- **Populations:** Appropriate for use in Type 1 diabetes, insulin-requiring Type 2 diabetes, gestational diabetes, and latent autoimmune diabetes. Omnipod can be used by people of all ages. See <https://www.myomnipod.com/healthcareproviders/about-omnipod/prescribe>.

- **Components:** 1) Adhesive disposable pump (Pod), 2) handheld Personal Diabetes Manager (PDM) device with *built-in* Abbott Freestyle blood glucose meter (BGM)
  - *Abbott FreeStyle* test strips and control solution are used with the Abbott FreeStyle BGM for quantitative measurement of blood glucose (BG) in fresh whole capillary blood from the finger, upper arm and palm.\*
- **Connectivity:** Wireless *radiofrequency communication* between the Pod and PDM-BGM device.\*\*
- **User guide and related resources:** <https://www.myomnipod.com/podder-support/resources-troubleshooting>

*\*The Abbott FreeStyle is intended for single-patient use and should not be shared. The BGM should not be used for the diagnosis of or screening for diabetes or for neonatal use.*

*\*\*Data may be uploaded to Insulet Glooko<sup>®</sup> software allowing sharing with caregivers and providers and access from anywhere (data sharing available from provider's office or personal computer - Apple Macintosh computers 2012 or older are not compatible). See <https://support.glooko.com/hc/en-us> for more information.*

### Omnipod DASH Insulin Management System

- **Use:** subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin.
- **Populations:** Appropriate for use in Type 1 diabetes, insulin-requiring Type 2 diabetes, gestational diabetes, and latent autoimmune diabetes. Omnipod DASH can be used by people of all ages. See <https://www.myomnipod.com/healthcareproviders/about-omnipod/prescribe>.
- **Components:** 1) Adhesive disposable pump (DASH Pod), 2) handheld DASH PDM device, 3) compatible Contour<sup>®</sup> Next One BGM
  - *Contour Next* test strips and control solution are used with the Contour Next One BGM for quantitative measurement of BG in fresh capillary whole blood drawn from the fingertips or palm.\*
- **Connectivity:** Wireless *Bluetooth communication* between the DASH Pod, DASH PDM, Contour Next BGM and, if desired, an iPhone (iPhone application does not include insulin management - view only).\*\*
- **User guide and related resources:** [https://www.myomnipod.com/DASH\\_Resource\\_Troubleshooting](https://www.myomnipod.com/DASH_Resource_Troubleshooting)

*\*The Contour Next One BGM is intended for single-patient use and should not be shared. The BGM should not be used for the diagnosis of or screening for diabetes or for neonatal use.*

*\*\*Data may be uploaded to Insulet provided Glooko<sup>®</sup> software allowing sharing with caregivers and providers and access from anywhere (Cloud capability data sharing available). See <https://support.glooko.com/hc/en-us> for more information.*

### **Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that V-Go, Omnipod, and Omnipod DASH are **medically necessary** when the following criteria are met:

#### **I. Initial Approval Criteria**

##### **A. Diabetes Mellitus (must meet all):**

1. Diagnosis of diabetes mellitus;
2. Prescribed by or in consultation with an endocrinologist;
3. If request is for V-Go, age  $\geq$  21 years;
4. Member has utilized one of the following insulin administration methods for at least the last 6 months (a or b):
  - a. Continuous insulin delivery system (*see Appendix B for examples*);
  - b. Multiple daily insulin injections (meets i and ii):
    - i. Administration of at least 3 daily injections of a basal and bolus insulin regimen (*see Appendix B for examples of basal [intermediate- or long-acting] and bolus [short- or rapid-acting] insulin*);
    - ii. History of suboptimal blood sugar control despite appropriate management - examples of suboptimal control include, but are not limited to, any of the following (a-f):
      - a) Repeated hypoglycemic events (BG  $<$  70 mg/dL);
      - b) Repeated episodes of diabetic ketoacidosis;
      - c) Wide blood sugar excursions;
      - d) Hypoglycemia unawareness;
      - e) Glycosylated hemoglobin level (HbA1c)  $\geq$  7.0;
      - f) "Dawn phenomenon" with fasting blood sugars repeatedly  $>$  200 mg/dL;
5. Member has monitored BG  $\geq$  4 times a day for at least the last 6 months;
6. Member or caregiver has completed a physician-directed comprehensive diabetes management program;
7. Request meets one of the following (a or b):
  - a. V-Go: number of devices does not exceed 30 per month;\*  
*\*For requests exceeding 30 devices per month, a clinical rationale with documentation supports the higher quantity.*
  - b. Omnid/omnipod DASH: number of Pods does not exceed 10 per month;\*  
*\*For requests exceeding 10 Pods per month, a clinical rationale with documentation supports the higher quantity.*

**Approval duration:**

**Medicaid/HIM:** V-Go (6 months), Omnipod/Omnipod DASH (Pods - 6 months, device - one every 4 years)

**Commercial:** V-Go (6 months or to the member's renewal date, whichever is longer), Omnipod/Omnipod DASH (Pods - 6 months or to the member's renewal date, whichever is longer, device - one every 4 years)

**B. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Diabetes Mellitus (must meet all):**

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;

2. Member is responding positively to therapy and is adherent to provider follow-up visits and training;
3. Request meets one of the following (a or b):
  - a. V-Go: number of devices does not exceed 30 per month;\*  
 \*For requests exceeding 30 devices per month, a clinical rationale with documentation supports the higher quantity.
  - b. Omnipod/Omnipod DASH: number of Pods does not exceed 10 per month;\*  
 \*For requests exceeding 10 Pods per month, a clinical rationale with documentation supports the higher quantity.

**Approval duration:**

**Medicaid/HIM:** V-Go (12 months), Omnipod/Omnipod DASH (Pods - 12 months, device - one every 4 years)

**Commercial:** V-Go (6 months or to the member’s renewal date, whichever is longer), Omnipod/Omnipod DASH (Pods - 6 months or to the member’s renewal date, whichever is longer, device - one every 4 years)

**B. Other diagnoses/indications (must meet 1 or 2):**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

**Approval duration: Duration of request or 6 months (whichever is less);** or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

BG: blood glucose	MDI: multiple daily doses of insulin
BGM: blood glucose meter	PDM: Personal Diabetes Manager
CSII: continuous subcutaneous insulin infusion	Pod: tubeless insulin pump
FDA: Food and Drug Administration	T1DM: type 1 diabetes mellitus
	T2DM: type 2 diabetes mellitus

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
<b>CONTINUOUS INSULIN DELIVERY SYSTEMS</b> Insulin pumps (with tubing [automated options available])	Varies	Varies

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
<ul style="list-style-type: none"> <li>• MiniMed™ System (530G, 630G, 670G)</li> <li>• MiniMed™ Paradigm Revel™</li> <li>• t:slim™ X2 Insulin Pump</li> </ul> <p><u>Insulin pumps (without tubing)</u></p> <ul style="list-style-type: none"> <li>• Omnipod Insulin Management System</li> <li>• Omnipod DASH Insulin Management System</li> </ul> <p><u>Insulin patches</u></p> <ul style="list-style-type: none"> <li>• V-Go 20, 30, 40 Wearable Insulin Delivery Device (disposable)</li> </ul>		
<p><b>INSULIN</b></p> <p><b>Human Insulin</b></p> <p><u>Short-acting:</u></p> <ul style="list-style-type: none"> <li>• Regular insulin (HumuLIN<sup>®</sup> R U-500, HumuLIN<sup>®</sup> R U-500 KwikPen<sup>®</sup>, HumuLIN<sup>®</sup> R [OTC], NovoLIN<sup>®</sup> R ReliOn [OTC], NovoLIN<sup>®</sup> R [OTC])</li> </ul> <p><u>Intermediate-acting:</u></p> <ul style="list-style-type: none"> <li>• Insulin NPH (HumuLIN<sup>®</sup> N KwikPen<sup>®</sup> [OTC], HumuLIN<sup>®</sup> N [OTC], NovoLIN<sup>®</sup> N ReliOn [OTC], NovoLIN<sup>®</sup> N [OTC])</li> </ul> <p><u>Intermediate-acting and short-acting combinations:</u></p> <ul style="list-style-type: none"> <li>• Insulin NPH and regular insulin (HumuLIN<sup>®</sup> 70/30, HumuLIN<sup>®</sup> 70/30 KwikPen<sup>®</sup>, NovoLIN<sup>®</sup> 70/30)</li> </ul> <p><b>Insulin Analogs</b></p> <p><u>Rapid-acting</u></p> <ul style="list-style-type: none"> <li>• Insulin glulisine (Apidra, Apidra SoloStar<sup>®</sup>)</li> <li>• Insulin lispro (Admelog, Admelog SoloStar<sup>®</sup>, HumaLOG<sup>®</sup>, HumaLOG Junior KwikPen<sup>®</sup>, HumaLOG KwikPen<sup>®</sup>,</li> <li>• Insulin aspart (Fiasp<sup>®</sup>, Fiasp FlexTouch<sup>®</sup>, NovoLOG<sup>®</sup>, NovoLOG FlexPen<sup>®</sup>, NovoLOG PenFill<sup>®</sup>)</li> </ul> <p><u>Intermediate-acting and short-acting combinations:</u></p> <ul style="list-style-type: none"> <li>• Insulin aspart protamine and insulin aspart (NovoLOG Mix<sup>®</sup> 70/30, NovoLOG Mix 70/30 FlexPen<sup>®</sup>)</li> <li>• Insulin lispro protamine and insulin lispro (HumaLOG Mix<sup>®</sup>, HumaLOG Mix<sup>®</sup> 50/50, HumaLOG Mix 50/50 KwikPen<sup>®</sup>, HumaLOG Mix<sup>®</sup> 75/25, HumaLOG Mix 75/25 KwikPen<sup>®</sup>)</li> </ul> <p><u>Long-acting</u></p> <ul style="list-style-type: none"> <li>• Insulin glargine (Basaglar KwikPen<sup>®</sup>, Lantus<sup>®</sup>, Lantus SoloStar<sup>®</sup>, Toujeo Max SoloStar<sup>®</sup>, Toujeo SoloStar<sup>®</sup>)</li> <li>• Insulin detemir (Levemir<sup>®</sup>, Levemir FlexTouch<sup>®</sup>)</li> <li>• Insulin degludec (Tresiba<sup>®</sup>, Tresiba FlexTouch<sup>®</sup>)</li> </ul>	Varies	Varies

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): Omnipod and Omnipod DASH Insulin Management Systems are not recommended for people who are:
  - Unable to perform at least 4 blood glucose tests per day
  - Unable to maintain contact with their healthcare provider
  - Unable to use the System according to instructions
- Boxed warning(s): none reported

**V. Dosage and Administration**

Drug Name	Dosing Regimen*	Maximum Dose
<p>V-Go Wearable (disposable) Insulin Delivery Device                      See User Guide for more information:  <a href="https://www.go-vgo.com/hcp/wp-content/uploads/sites/2/2019/12/ART-1361-Rev-A-V-Go-IFU-2019-V4.pdf">https://www.go-vgo.com/hcp/wp-content/uploads/sites/2/2019/12/ART-1361-Rev-A-V-Go-IFU-2019-V4.pdf</a></p>	<p>V-Go is designed for 24-hour wear and requires one insulin type - U-100 fast-acting insulin. Humalog (insulin lispro, rDNA origin) and NovoLog (insulin aspart, rDNA origin) have been tested and found to be safe for use in V-Go.</p> <ul style="list-style-type: none"> <li>• <u>Stability and storage:</u> Humalog has been tested in V-Go and has been demonstrated to be stable for up to 24 hours refrigerated or at room temperature followed by 24 hours wear. NovoLog has been demonstrated to be stable for up to 5 days refrigerated or 3 days at room temperature followed by 24 hours wear. The EZ Fill has been demonstrated to be acceptable for filling Humalog and NovoLog for up to 30 days.</li> <li>• <u>Description:</u> V-Go is a mechanical (no electronics), self-contained, sterile, patient fillable, single-use disposable insulin infusion device with an integrated stainless steel subcutaneous needle. It is designed for the subcutaneous infusion of insulin. After filling V-Go with insulin using the EZ Fill, V-Go is secured to the patient's skin over the infusion site with an adhesive backed foam pad. Once activated, V-Go delivers a continuous infusion of insulin at a fixed rate. V-Go also allows the user to initiate bolus injections to supplement their daily basal insulin requirements. A window in the top of the device allows the user to see into the reservoir to check the drug and to monitor the progress of the infusion.</li> </ul>	<p>Varies by device</p>

Drug Name	Dosing Regimen*	Maximum Dose
<p>Omnipod Insulin Management System <i>See User Guide for more information:</i> <a href="https://www.myomnipod.com/sites/default/files/media/documents/17845-5A-AW_003_02.pdf">https://www.myomnipod.com/sites/default/files/media/documents/17845-5A-AW_003_02.pdf</a></p> <p>Omnipod DASH Insulin Management System <i>See User Guide for more information:</i> <a href="https://www.myomnipod.com/sites/default/files/media/documents/18296-ENG-AW_006_02-DASH-User-Guide-English.pdf">https://www.myomnipod.com/sites/default/files/media/documents/18296-ENG-AW_006_02-DASH-User-Guide-English.pdf</a></p>	<ul style="list-style-type: none"> <li>● Initial Omnipod and Omnipod DASH System use                             <ul style="list-style-type: none"> <li>○ Provider recommends initial program settings and meets with patient and Omnipod System Trainer to program the PDM device and first Pod.</li> </ul> </li> <li>● Filling the Pod                             <ul style="list-style-type: none"> <li>○ The Pod is filled with insulin FDA approved for insulin pumps (i.e., the following rapid-acting U100 insulin analogs: insulin glulisine (Apidra), insulin lispro (Admelog, HumaLOG), insulin aspart (Fiasp, NovoLOG)).</li> <li>○ Pod capacity accommodates 85 to 200 units of insulin depending on patient need (<i>for initial programming, each Pod must be filled with at least 85 units of insulin</i>).</li> </ul> </li> <li>● Pod priming                             <ul style="list-style-type: none"> <li>○ The PDM device and Pod are placed next to each other so that the PDM may prime the Pod.</li> </ul> </li> <li>● Pod placement                             <ul style="list-style-type: none"> <li>○ For site selection, see User Guides.</li> </ul> </li> <li>● Pod activation                             <ul style="list-style-type: none"> <li>○ The Pod features an insulin-providing cannula that inserts automatically with the press of an “activate” button on the PDM device.</li> </ul> </li> <li>● Pod replacement                             <ul style="list-style-type: none"> <li>○ The Pod may remain on the skin from 1 to 3 days after which a new Pod should be filled, primed, applied, and activated.</li> </ul> </li> </ul>	<p>200 units per day (1 Pod)</p>

\*The dosing regimen applies to the Omnipod and Omnipod DASH systems; however, each system’s Pods and devices are not interchangeable.

## VI. Product Availability

Drug Name	Availability
<p>V-Go 20, 30, 40</p>	<ul style="list-style-type: none"> <li>● V-Go is available as a 30-day supply in 3 options - V-Go 20, V-Go 30, and V-Go 40.</li> </ul>
<p>Omnipod Insulin Management System <i>All Omnipod components (Pod, PDM, built-in BGM) have wireless radiofrequency connectivity that is not compatible with smartphones.</i></p>	<ul style="list-style-type: none"> <li>● Omnipod Pack 5, 10 (packs of 5 or 10 Pods)</li> <li>● Starter Kit (PDM device with built-in FreeStyle BGM)*</li> </ul> <p><i>*The built-in FreeStyle BGM must be used with Abbott FreeStyle test strips and control solution; however, patients may choose to use other blood glucose testing methods with manual entry into the PDM device.</i></p>

Drug Name	Availability
<p>Omnipod DASH Insulin Management System <i>All Omnipod DASH components (Pod, PDM, compatible BGM) have Bluetooth connectivity that is compatible with the iPhone.</i></p>	<ul style="list-style-type: none"> <li>● Omnipod Pack 5 (packs of 5 Pods)</li> <li>● Starter Kit (PDM DASH device plus a separate but compatible Contour<sup>®</sup> Next One BGM)*</li> </ul> <p><i>*The compatible Contour Next One BGM must be used with Ascensia Contour<sup>®</sup> Next test strips and control solution; however, patients may choose to use other blood glucose testing methods with manual entry into the PDM device.</i></p>

## VII. References

### **V-Go**

#### *FDA 510(k) device summary*

1. V-Go Insulin Delivery System 510(k) summary, No. K103825. Shrewsbury, MA: Valeritas, Inc.; February 2011. Available at: [https://www.accessdata.fda.gov/cdrh\\_docs/pdf10/K103825.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf10/K103825.pdf). Accessed August 14, 2020.

#### *User guides*

2. Instructions for Patient Use. P/N 2614-00 Rev. A 05/2019. Available at <https://www.go-vgo.com/hcp/wp-content/uploads/sites/2/2019/12/ART-1361-Rev-A-V-Go-IFU-2019-V4.pdf>. Accessed August 14, 2020.

#### *Clinical trials and reviews*

3. Grunberger G, Rosenfeld CR, Bode BW, Abbott SD, Nikkel C, Shi L, Strange P. Effectiveness of V-Go for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study. *Drugs Real World Outcomes*. 2020 Mar;7(1):31-40. 5.
4. Sutton D, Higdon C, Nikkel C, Hilsinger K. Clinical benefits over time associated with use of V-Go Wearable Insulin Delivery Device in adult patients with diabetes: a retrospective analysis. *Advances in Therapy* 2018 May; 35(5): 631-43.
5. Lajara R, Fetchick DA, Morris DA, Nikkel C. Use of V-Go<sup>®</sup> insulin delivery device with sub-optimally controlled diabetes mellitus: a retrospective analysis from a large specialized diabetes system. *Diabetes Ther*. 2015;6(4):531-545.
6. Lajara R, Davidson JA, Nikkel C, Morris TL. Clinical and cost effectiveness of insulin delivery with V-Go disposable insulin delivery device versus multiple daily injections in patients with type 2 diabetes inadequately controlled on basal insulin. *Endocrine Practice* 2016 June;22(6):726-735.

### **Omnipod, Omnipod DASH**

#### *FDA 510(k) device summary*

7. Omnipod Insulin Management System and Omnipod DASH Insulin Management System 510(k) summary, No. K192659. Acton, MA: Insulet Corporation; October 2019. Available at: [https://www.accessdata.fda.gov/cdrh\\_docs/pdf19/K192659.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192659.pdf). Accessed February 10, 2020.

#### *User guides*

8. Omnipod Insulin Management System. Podder's Handbook User Guide. Available at [https://www.myomnipod.com/sites/default/files/media/documents/17845-5A-AW\\_003\\_02.pdf](https://www.myomnipod.com/sites/default/files/media/documents/17845-5A-AW_003_02.pdf). Accessed August 14, 2020.
9. Omnipod DASH Insulin Management System. Podder's Handbook User Guide. Available at [https://www.myomnipod.com/sites/default/files/media/documents/18296-ENG-AW\\_006\\_02-DASH-User-Guide-English.pdf](https://www.myomnipod.com/sites/default/files/media/documents/18296-ENG-AW_006_02-DASH-User-Guide-English.pdf). Accessed August 14, 2020.



*Clinical trials and reviews*

10. Layne JE, Parkin CG, Zisser H. Efficacy of the Omnipod Insulin Management System on glycemic control in patients with type 1 diabetes previously treated with multiple daily injections or continuous subcutaneous insulin infusion. *J Diabetes Sci Technol.* 2016;10(5):1130-1135.
11. Layne JE, Parkin CG, Zisser H, et al. Efficacy of a tubeless patch pump in patients with type 2 diabetes previously treated with multiple daily injections. *J Diabetes Sci Technol.* 2017;11(1):178-179.
12. Ly TT, Layne JE, Huyett LM, et al. Novel Bluetooth-enabled tubeless insulin pump: innovating pump therapy for patients in the digital age. *J Diabetes Sci Technol.* 2019;13(1):20-26.

**Insulin Products**

13. Lexicomp Online, Insulin Lexi-Drugs Online, Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2020. Accessed February 10, 2020.

**Continuous Insulin Delivery Systems**

14. Diabetes technology: Standards of medical care in diabetes. American Diabetes Association. *Diabetes Care* 2020 Jan; 43 (Supplement 1): S77-S88. <https://doi.org/10.2337/dc20-S007>.
15. Grunberger G, Handelsman Y, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology 2018 position statement on integration of insulin pumps and continuous glucose monitoring in patients with diabetes mellitus. *Endocrine Practice*; March 2018: 24(3): 302-308.
16. Peters AL, Ahmann AJ, Hirsch IB, et al. Advances in glucose monitoring and automated insulin delivery: supplement to Endocrine Society clinical practice guidelines. *J Endocr Soc*; October 5 2018; 2(11): 1214-1225.

**Diabetes and Pregnancy**

17. Blumer I, Hadar E, Hadden DR, et al. Diabetes and Pregnancy: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* November 2013; 98(11): 4227-49.
18. Guideline for detection and management of diabetes in pregnancy. Joslin Diabetes Center and Joslin Clinic. November 10, 2016, January 11, 2107. Available at [https://www.joslin.org/Pregnancy-Guidelines\\_11-13-2016\\_corrected\\_1-11-2017.pdf](https://www.joslin.org/Pregnancy-Guidelines_11-13-2016_corrected_1-11-2017.pdf). Accessed April 22, 2019.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description*
A9274	External ambulatory insulin delivery system (Pod)
E0784	External ambulatory infusion pump, insulin (PDM device)

\*A9274 and E0784: Omnipod System (the codes do not apply to Omnipod DASH); A9274: V-Go..

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created. CP.PHAR.420 Insulin Infusion Pump (Omnipod, Omnipod DASH) policy is retired and integrated into the present policy; V-Go wearable insulin delivery device added to the policy; Dawn phenomenon fasting blood sugar corrected - from 200 g/dL to 200 mg/dL; rapid-acting insulin analog Fiasp added to Omnipod / Omnipod DASH approved insulins; t:slim pump added to Appendix B; references reviewed and updated.	08.25.20	11.20

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2020 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.